【摘要】 目的探讨拉米夫定和干扰素-2α治疗慢性乙型肝炎肝纤维化的疗效。方法68例HBV-DNA及HBeAg阳性的慢性乙型肝炎同期患者分为甲、乙两组。甲组采用拉米夫定,乙组采用干扰素-2α。治疗24周时,观察两组治疗前后ALT、HBV-DNA、HBeAg及肝纤维化指标的变化。结果治疗24周时,甲、乙两组ALT复常率分别为83%和85%;HBV-DNA阴转率分别为84%和85%,以上指标两组相比,差异无统计学意义(P>0.05);HBeAg阴转率分别为20%和50%,两组相比差异有统计学意义(P<0.05)。肝纤维化指标:甲、乙两组治疗前后分别为血清透明质酸281.3±112.6、78.4±56.5和275.4±107.4、80.6±46.9;Ⅲ型前胶原蛋白167.2±94.3、91.4±46.6和163.1±96.4、89.8±41.9;Ⅳ型胶原蛋白120.8±111.3、60.2±40.2和119.4±113.2、61.5±341.3。以上指标治疗前后相比,差异均有统计学意义(P<0.01)。两组之间治疗后肝纤维化指标的比较,差异无统计学意义(P>0.05)。结论拉米夫定、干扰素-2α具有抗病毒、抗纤维化的作用。更多还原

【Abstract】 Objective To explore the clinical effects of lamivudine and interferon-2α in treating liver fibrosis due to chronic hepatitis B.Methods Sixty-eight patients who had HBV-DNA and HBeAg positive chronic hepatitis B were divided into group A and group B,in which the lamivudine and interferon-2α were administered respectively.After 24 weeks treatment,the changes of ALT,HBV-DNA,HBeAg and the indexes of liver fibrosis were observed in both groups.Results Twenty-four weeks later,the normalization rate of group A and group B was 83%,85% respectively and the negative-conversion rate of HBV-DNA was 84%,85% respectively,no significant differences were seen between two groups(P>0.05).However,the negative-conversion rate of HBeAg in group A and group B was 20%,50% respectively,with significant difference(P<0.05).The indexes of liver fibrosis before and after treatment in two groups were shown as follows:HA:281.3±112.6,78.4±56.5 and 275.4±107.4,80.6±46.9;PCⅢ:167.2±94.3,91.4±46.6 and 163.1±96.4,89.8±41.9;C-Ⅳ:120.8±111.3,60.2±40.2 and 119.4±113.2,61.5±341.3.In those indexes,the significant differences were seen before and after treatment in each group(P<0.01) but not seen between two groups after treatment.Conclusion Lamivudine and interferon-2α have the effects of antivirus and anti-fibrosis.更多还原